Background
==========

Hepatocellular carcinoma (HCC) is the sixth most common cancer and the second most common cause of death from cancer worldwide \[[@b1-medscimonit-25-2452],[@b2-medscimonit-25-2452]\]. Around 50% of newly diagnosed cases occur in China. HCC is highly vascularized with frequent intrahepatic and extrahepatic metastasis, which is responsible for the rapid recurrence and poor survival \[[@b3-medscimonit-25-2452],[@b4-medscimonit-25-2452]\]. In the past few decades, although progress has been made in the clinical management of HCC, prognosis has not improved substantially \[[@b5-medscimonit-25-2452],[@b6-medscimonit-25-2452]\].

Single nucleotide polymorphisms (SNPs) are the most common form of genetic variation in the human genome. They are related to risk and heterogeneity in human diseases, clinical course, and response to treatment \[[@b7-medscimonit-25-2452],[@b8-medscimonit-25-2452]\]. Although studies have demonstrated associations between SNPs in specific candidate genes for HCC and outcome, the prognostic value of these germline variants remains controversial \[[@b9-medscimonit-25-2452]--[@b11-medscimonit-25-2452]\].

Genome-wide interrogation, which is independent of a priori hypotheses, has emerged as a powerful tool for identifying genetic variants associated with the length of survival for different types of cancer \[[@b12-medscimonit-25-2452]--[@b16-medscimonit-25-2452]\]. While the candidate gene approach is based on our relatively limited understanding of tumor and host biology, the genome-wide interrogation approach allows a more comprehensive evaluation of germline variants across the whole genome \[[@b12-medscimonit-25-2452]\]. For HCC, several genome-wide association studies (GWASs) have identified genetic variants at genomic *loci* 1p36.22, 6p21.32, 7q21.13, and 21q21.3, in *STAT4* and *HLA-DQ*, and in the HLA class I region that confer susceptibility in chronic hepatitis B virus carriers \[[@b17-medscimonit-25-2452]--[@b21-medscimonit-25-2452]\]. However, little is known about genomic *loci* associated with the survival of patients with HCC.

In this study, we first conducted a GWAS of 367 patients with HCC to identify SNPs associated with outcome. With the aim of building a survival prediction model, the prognostic values of SNPs were further evaluated in a replication set of 758 cases. The survival prediction model was then validated in an independent set of 316 patients and combined with TNM stage to construct a new model that included "seed and soil" factors. According to this model, the SNP rs2431, which is located in the 3′ untranslated region (3′ UTR) of *FNDC3B*, regulates the expression level of this metastasis-promoting gene by affecting the binding of miR-409-3p.

Material and Methods
====================

Study design
------------

A total of 1802 patients with HCC who underwent liver resection at the authors' institutes between 2004 and 2009 were recruited. Among these patients, 1441 were enrolled in the SNP genotyping study: 1) the discovery set consisted of 367 patients for genome-wide interrogation of *loci* related to survival; 2) the replication set consisted of 758 patients to further evaluate the prognostic value of SNPs, and the discovery and replication sets were combined to construct a genetic prediction model for postoperative survival in patients with HCC; 3) the independent validation set consisted of 316 patients to test the prognostic value of the 5-SNP survival prediction model. Formalin-fixed and paraffin-embedded tissues of the remaining 361 patients were used to construct a tissue microarray for immunohistochemical (IHC) analyses. The flow of the study is illustrated in [Figure 1](#f1-medscimonit-25-2452){ref-type="fig"}.

Patients and specimens
----------------------

This study was approved by the Research Ethics Committee of Fudan University (2017-041). No patients in this study received preoperative cancer treatment before curative resection for HCC, and all patients were followed up until April 2014. All of the samples included in this study had no visible residual tumor after curative resection. All patients with hepatitis B virus (HBV)-related/hepatitis C virus (HCV)-related HCC received antiviral therapy. No patients included in this study received molecular targeted therapy. Data on survival or death and clinicopathological characteristics were recorded for all participating individuals. Overall survival (OS) was calculated from the date of surgery to the date of last follow-up or death. During the follow-up period, patients were examined every 2--3 months after the operation. Computed tomography or magnetic resonance imaging was performed when tumor recurrence was suspected. Snap-frozen or paraffin-embedded tissue samples and blood were obtained from patients after obtaining written informed consent. All tumors were confirmed to be HCC by 2 independent pathologists. Histological grade was staged using the TNM stage system of the Union for International Cancer Control/American Joint Committee on Cancer (2010).

DNA extraction and genotyping
-----------------------------

In the discovery set, genomic DNA of each study participant was extracted from blood samples using the Quick Gene DNA Whole Blood Kit (Fujifilm, Osaka, Japan) and genotyped using GeneChip Axiom Genome-Wide Human ASI (Affymetrix, Santa Clara, CA, USA). A total of 367 samples and 630 573 SNPs were used in the final GWAS. In the replication and validation sets, genomic DNA from each participant was extracted from tumor-adjacent tissue samples using the QIAamp DNA Mini Kit (Qiagen, Hilden, Germany), and chosen SNPs were genotyped using MassARRAY (Sequenom, San Diego, CA, USA).

Quality control
---------------

Systematic quality control was performed on genotyping data from the GWAS and Sequenom MassArray data using PLINK, including 95% SNP and 90% individual call rate thresholds; the number of samples excluded from analyses is shown in [Figure 1](#f1-medscimonit-25-2452){ref-type="fig"}. For each sample set, the genotype counts and Hardy-Weinberg equilibrium (HWE) results are shown in [Supplementary Table 1](#s1-medscimonit-25-2452){ref-type="supplementary-material"}. The call rates for 5 selected SNPs in each sample set were all \>95%. In the entire cohort, the HWE results were χ^2^=0.191, *P*=0.662 for rs10793585; χ^2^=4.822, *P*=0.028 for rs2431; χ^2^=0.890, *P*=0.169 for rs34675408; χ^2^=0.233, *P*=0.629 for rs6078460; χ^2^=0.077, *P*=0.782 for rs6766361. No significant deviation from HWE was detected (*P*≤0.001). To evaluate the genotyping quality, we genotyped the 23 SNPs in 30 randomly selected genome-wide scan samples using Sequenom MassArray, and the concordance between the 2 methods was \>95%.

Detection of protein levels by western blotting
-----------------------------------------------

Total protein was extracted, separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), and transferred onto polyvinylidene fluoride membranes (Millipore, Billerica, MA, USA). The following antibodies were used: anti-FNDC3B (ab135714; Abcam, Cambridge, UK), anti-GAPDH (CST), and goat-anti-rabbit IgG conjugated to horseradish peroxidase (HRP; Cwbiotech), which was used as the secondary antibody. Protein was detected by Image Acquisition using ImageQuant™ LAS 4000 (GE Healthcare Life Sciences, Marlborough, MA, USA).

Dual luciferase reporter assay
------------------------------

HEK293T or Hep3B cells were seeded in a 96-well plate at 50% to 60% confluence. After 24 hours, cells were transfected with 120 ng of pWPI-miR-409-3p vector or control vector, and co-transfected with 30 ng of the 3′UTR of *FNDC3B* vector containing the rs2431\[G\] or rs2431\[A\] alleles using 0.45 μL of Fugene (Promega). Cells were collected 48 hours after transfection, Firefly and Renilla luciferase activity was measured using a dual-luciferase reporter system (Promega). Luciferase reporter assays were performed in duplicate and repeated in 3 independent experiments. Luciferase activity was detected using an Orion II microplate luminometer (Berthold Technologies, Bad Wildbad, Germany).

IHC staining analysis
---------------------

Formalin-fixed and paraffin-embedded tissues were used for IHC staining. The rabbit polyclonal antibody to FNDC3B (HPA007859; Sigma-Aldrich, St. Louis, MO, USA) was incubated with the tissue sections or microarrays at 4°C overnight and detected using the GTVision™ II Kit (HRP/DAB, Rabbit/Mouse; Genetech, San Francisco, CA, USA). Staining intensity was scored manually by 2 independent experienced pathologists as follows: 0=no staining, 1=weak staining, 2=moderate staining, and 3=strong staining. Tissue sections or microarrays were scored based on the percentage of positively stained cells (0--100%). The final IHC reaction score (IRS) was calculated as the sum of the products of the intensity score and the percentage of positive cells.

Cell lines and cell culture
---------------------------

Four human HCC cell lines (MHCC97-H, HCCLM3, Huh7, and Hep3B), and one human embryonic kidney cell line (HEK293T) were used in this research. MHCC97-H and HCCLM3 were established at the Liver Cancer Institute and Zhongshan Hospital, Fudan University and have high metastatic potential; Huh7, Hep3B, and HEK293T were obtained from the American Type Culture Collection (Manassas, VA, USA). All cell lines were maintained in Dulbecco's modified Eagle's medium (DMEM; Hyclone, Logan, UT, USA) with 10% fetal bovine serum (FBS; Gibco, Gaithersburg, MD, USA) at 37°C and 5% CO~2~.

Statistical analysis
--------------------

Genotype quality control was performed within each study population using PLINK. For the GWAS and replication of survival data, multiple linear regression was performed for each SNP and case. Linkage disequilibrium (LD) between genotyped SNPs on the same chromosome was determined using Haploview version 4.2 (Broad Institute). TAGster was used for tag SNP selection, and LD was measured by *r*^2^ with a threshold of 0.8 and a maximum distance between SNPs of 250 kb. Genotype data for SNPs were obtained from dbSNP (April 2009) for the Asian population. A principal component analysis (PCA)-based method implemented in the software package GCTA was used to detect population outliers and stratification. Kaplan-Meier and χ^2^ tests were implemented in SPSS version 16.0 (SPSS Inc., Chicago, IL, USA). *P-*values for survival analyses were obtained using log-rank tests. The Cox proportional hazard model was applied for univariate and multivariate analyses to evaluate the effect of each clinical variable, including hazard ratios (HRs) and their 95% confidence intervals (CIs), and to construct a survival predicted model. Nomogram, receiver operating characteristics (ROC) curves, and the calibration curve were plotted using R version 3.3.3, and the nearest neighbor estimate was used for the ROC analysis. HWE was evaluated using χ^2^ tests.

Results
=======

Patient characteristics
-----------------------

Detailed clinicopathological characteristics of participants in the discovery, replication, and validation sets are presented in [Table 1](#t1-medscimonit-25-2452){ref-type="table"}. No significant differences in clinicopathologic features were observed among the discovery, replication, and validation sets. Among the selected characteristics, TNM stage, Barcelona Clinic Liver Cancer (BCLC) stage, Child-Pugh stage, serum alpha-fetoprotein (AFP) concentration, tumor size, tumor number, vascular invasion, portal vein tumor thrombus, extrahepatic metastasis, tumor differentiation, and tumor encapsulation were significantly associated with survival ([Supplementary Table 2](#s2-medscimonit-25-2452){ref-type="supplementary-material"}). The characteristics of the 361 cases for tissue microarrays used for IHC analyses are shown in [Supplementary Table 3](#s3-medscimonit-25-2452){ref-type="supplementary-material"}.

Selection of SNPs associated with survival length in HCC
--------------------------------------------------------

After standard quality filtering, 630 573 SNPs and 367 cases were used for genome-wide interrogation of survival length ([Figure 2](#f2-medscimonit-25-2452){ref-type="fig"}). PCA showed little evidence of population stratification in our study populations; therefore, no principal component was adjusted in subsequent association analyses ([Supplementary Figure 1A](#s14-medscimonit-25-2452){ref-type="supplementary-material"}). The effect of genotypes on OS was investigated using multiple linear regression \[[@b22-medscimonit-25-2452]\]. A quantile-quantile plot revealed a good match between the distributions of observed *P*-values and those expected by chance ([Supplementary Figure 1B](#s14-medscimonit-25-2452){ref-type="supplementary-material"}).

Among all SNPs, only 6 met the standard threshold (*P*\<10^−5^) for GWAS. Our limited sample size for the discovery set (n=367) might not be sufficient for optimal statistical power. To identify as many significant features for validation as possible, we defined the threshold as *P*\<10^−3.5^ and identified 149 SNPs that were significantly associated with the length of survival. The 6 SNPs that met the *P*\<10^−5^ threshold were directly included in the replication stage. Combined the results of Kaplan-Meier analyses (*P*\<0.001), 23 candidate SNPs were selected ([Supplementary Table 4](#s4-medscimonit-25-2452){ref-type="supplementary-material"}) for further evaluation in an independent replication set of 758 samples using MassARRAY. Among them, 8 SNPs were located in functional regions of genes, such as the 3′UTR, 5′UTR, or coding sequence (CDS).

In the replication set, 7 of the 23 SNPs (rs10790836, rs10893585, rs11600756, rs2431, rs34675408, rs6078460, and rs6766361) were significantly associated with OS in HCC (*P*\<0.05, [Table 2](#t2-medscimonit-25-2452){ref-type="table"}). The association between the 23 SNPs and the time to recurrence was also analyzed, and all 7 SNPs showed significant predictive value in the combined sample set ([Supplementary Table 5](#s5-medscimonit-25-2452){ref-type="supplementary-material"}). Three SNPs (rs10790836, rs10893585, and rs11600756) located on Chr.11q24 were in strong LD and could be tagged by rs10893585 (*r*^2^=0.8272 for rs10790836, *r*^2^=0.8511 for rs11600756).

According to Kaplan-Meier estimates, genotypes of each SNP could be subdivided into benign and malignant. OS was significantly longer for CT+TT than CC, AA than AG+GG, TT than GT, AG+GG than AA, and AA+CA than CC for rs10893585, rs2431, rs34675408, rs6078460, and rs6766361, respectively ([Supplementary Figure 2](#s15-medscimonit-25-2452){ref-type="supplementary-material"}). To further evaluate the prognostic value of the 5 selected SNPs, multivariate analyses using Cox proportional hazards regression models were performed using the combined cohort. Significant individual features from the univariate analysis were adopted as covariates. The SNPs were independent prognostic indicators of the length of survival ([Supplementary Table 6](#s6-medscimonit-25-2452){ref-type="supplementary-material"}).

Construction and validation of an SNP survival prediction model
---------------------------------------------------------------

To further define an SNP panel that could accurately predict prognosis in patients with HCC after curative resection, we applied the Cox proportional hazards regression model to estimate the risk of long-term survival using an entry procedure on the combined discovery and replication sets. The Cox *P*-values for all 5 SNPs were less than 0.05 ([Supplementary Table 7](#s7-medscimonit-25-2452){ref-type="supplementary-material"}). For each SNP, the Cox coefficient was set as the final value for further calculations to obtain a survival prediction model. The predicted survival value, which could be defined as the Cox index, of different haplotypes was calculated based on the following 5-SNP panel:
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Categorical genotypes were coded as follows: CC as 1 and CT+TT as 0 for rs10893585; AA as 1 and AG+GG as 0 for rs2431; GT as 1 and TT as 0 for rs34675408; AA as 1 and AG+GG as 0 for rs6078460; AA+CA as 1 and CC as 0 for rs6766361. In the model, a higher score indicated poorer prognosis.

The prognostic performance of the SNP scoring system was evaluated by ROC analysis and Harrell's c-index. The area under the ROC curve for 5-year survival was 0.716 (95% CI: 0.683--0.746), better than that for any single SNP ([Supplementary Figure 3](#s16-medscimonit-25-2452){ref-type="supplementary-material"}), and the c-index was 0.666 (95% CI: 0.642--0.689). Using the optimal cutoff value (−0.057) determined from the ROC curve, the sensitivity and specificity of the 5-SNP survival prediction model were 58.8% and 74.8%, respectively. Then, Kaplan-Meier analyses were used to evaluate the prognostic performance of the 5-SNP prediction model using the discovery and replication sets( [Figure 3A, 3B](#f3-medscimonit-25-2452){ref-type="fig"}). According to the cutoff value of the model, the patients were subdivided into high-risk (higher prediction value) and low-risk (lower prediction value) groups. A significantly longer survival time was found in low-risk patients than in high-risk patients in the combined set, with median OS of 100.1 and 35.5 months, respectively (HR=1.725, *P*=1.45×10^−10^; [Figure 3C](#f3-medscimonit-25-2452){ref-type="fig"}, [Supplementary Table 8](#s8-medscimonit-25-2452){ref-type="supplementary-material"}). To further evaluate the prognostic value of the 5-SNP prediction model, multivariate analyses using Cox proportional hazards regression models were performed for each set. The 5-SNP prediction model was an independent prognostic indicator of OS ([Supplementary Table 9](#s9-medscimonit-25-2452){ref-type="supplementary-material"}).

The prediction model was analyzed using another independent validation set. Kaplan-Meier survival curves provided strong evidence for the reliability of predictions in the validation set, with median OS times of 80.2 and 48.0 months, respectively (HR=1.481, *P*=0.002; [Figure 3D, 3E](#f3-medscimonit-25-2452){ref-type="fig"}, [Supplementary Table 8](#s8-medscimonit-25-2452){ref-type="supplementary-material"}). In addition, multivariate analyses also demonstrated that the 5-SNP prediction model was an independent prognostic factor for OS ([Supplementary Table 9](#s9-medscimonit-25-2452){ref-type="supplementary-material"}). Furthermore, the association between the 5-SNP prediction model and recurrence-free survival (RFS) was also analyzed, and in all sample sets, significantly longer RFS times were found in low-risk patients than in high-risk patients ([Supplementary Table 10](#s10-medscimonit-25-2452){ref-type="supplementary-material"}).

Combining the SNP prediction model with TNM stage
-------------------------------------------------

In addition to the 5-SNP prediction model, multivariate analyses showed that various clinicopathologic features, such as tumor number, tumor size, and tumor invasion, were also independent factors for survival in HCC. To explore whether tumor-specific characteristics could complement and strengthen the SNP algorithm, we added TNM stage data, which is a comprehensive summary of these clinicopathological features, to the 5-SNP prediction model using a Nomogram strategy ([Figure 4A](#f4-medscimonit-25-2452){ref-type="fig"}).

*P*-values for all variables in the Nomogram model were less than 0.05 ([Supplementary Table 11](#s11-medscimonit-25-2452){ref-type="supplementary-material"}). The predicted survival value for HCC, which could be defined as the Nomogram index, for different haplotypes can be calculated based on the 5 SNPs and the TNM stage as follows:
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In the model, the higher the score, the worse the prognosis.

Harrell's c-index of the Nomogram for predicting survival was 0.723 (95% CI: 0.701--0.745), which was significantly higher than those of the SNPs or the TNM stage alone (SNPs: 0.666, *P*=2.33×10^−4^; TNM stage: 0.654 (95% CI: 0.632--0.676), *P*=5.80×10^−6^; [Figure 4B](#f4-medscimonit-25-2452){ref-type="fig"} (left)). The result was confirmed using the validation set with a Harrell's c-index of the Nomogram of 0.714 (95% CI: 0.673--0.755), which was significantly higher than those of SNPs or TNM stage alone (SNPs: 0.648 (95% CI: 0.606--0.691), *P*=0.014; TNM stage: 0.652 (95% CI: 0.610--0.694), *P*=0.018; [Figure 4B](#f4-medscimonit-25-2452){ref-type="fig"} (right)). The calibration plots for the probability of survival at 3 or 5 years after surgery also showed optimal agreement between the prediction by Nomogram and actual observation in the combined set and validation set ([Figure 4C](#f4-medscimonit-25-2452){ref-type="fig"}).

The area under the ROC curve for 5-year survival was 0.766 (95% CI: 0.735--0.796), which was significantly higher than those for the SNPs or TNM stage alone (SNP: 0.716, *P*=0.011; TNM stage: 0.698 (95%CI: 0.664--0.731), *P*=0.002; [Supplementary Figure 4](#s17-medscimonit-25-2452){ref-type="supplementary-material"}). Using the optimal cutoff value (0.695) determined from the ROC curve, the sensitivity and specificity of the Nomogram survival prediction model were 69.6% and 73.2%, respectively.

Kaplan-Meier survival curves also provided strong evidence for the reliability of predictions in the combined (discovery and replication) set and validation set. Survival time was significantly longer for patients with lower prediction values than for patients with higher prediction values, with median OS times of 100.1 versus 30.8 months and 82.2 versus 22.5 months, respectively (HR=2.512, *P*=6.52×10^−24^; HR=2.415, *P*=2.33×10^−10^, respectively; [Figure 4D](#f4-medscimonit-25-2452){ref-type="fig"}, [Supplementary Table 12](#s12-medscimonit-25-2452){ref-type="supplementary-material"}). Similar results were obtained using the discovery set, replication set, and the entire cohort ([Supplementary Figure 5](#s18-medscimonit-25-2452){ref-type="supplementary-material"}, [Supplementary Table 12](#s12-medscimonit-25-2452){ref-type="supplementary-material"}). Furthermore, we compared RFS times between groups with lower and higher prediction values divided by the Nomogram prediction model in each sample set, and found that the Nomogram prediction model was significantly associated with the RFS ([Supplementary Table 13](#s13-medscimonit-25-2452){ref-type="supplementary-material"}.).

To assess the reliability of the 5-SNP prediction model and the Nomogram prediction model for the prediction of HCC prognosis, we conducted a subgroup analysis of patients with different clinical parameters that were not included in our prognostic model, such as gender, age, serum AFP level, serum alanine aminotransferase level, liver cirrhosis status, and BCLC stage. The Nomogram prediction model showed excellent prognostic performance in all subgroups, while the 5-SNP prediction model showed very good prognostic performance in most subgroups, except in the female subgroup ([Table 3](#t3-medscimonit-25-2452){ref-type="table"}).

Functional relevance of rs2431
------------------------------

To understand the mechanism by which genetic variants influence HCC prognosis, we performed functional analyses of the SNPs included in the prediction model. Among the 5 SNPs, rs2431 and rs34675408 were located in the 3′ UTR of *FNDC3B* and the exonic region of *OSMR*, respectively. Taking the genotype frequencies into account, we focused on rs2431.

Genetic variants in the 3′ UTR might influence gene expression via gain or loss of the binding site of microRNAs involved in regulation \[[@b23-medscimonit-25-2452]--[@b27-medscimonit-25-2452]\]. Therefore, we first obtained data from SNPinfo (*<http://www.niehs.nih.gov/snpinfo>*) and found that miR-409-3p is the only miRNA that exerts diverse effects when binding to different alleles. Dual-luciferase reporter assays showed that the binding between miR-409-3p and rs2431\[G\] was significantly weaker than binding to rs2431\[A\] ([Figure 5A](#f5-medscimonit-25-2452){ref-type="fig"}). In addition, we investigated the genotype of rs2431 in four HCC cell lines, and found the GG genotype in MHCC97-H and HCCLM3 and AA genotype in Huh7 and Hep3B. Interestingly, the overexpression of miR-409-3p induced much greater suppression of FNDC3B expression in cell lines harboring the rs2431\[A\] allele than in those with the rs2431\[G\] allele ([Figure 5B](#f5-medscimonit-25-2452){ref-type="fig"}). By IHC staining in 60 HCC tissues randomly selected from the 1125 genotyped samples, we found that HCC tissues with the rs2431\[G\] allele had significantly higher FNDC3B IHC reaction scores (IRS) (1.500±0.097; n=30) than those of tissues with the rs2431\[A\] allele (1.050±0.124; n=30) (*P*=0.0034; [Figure 5C](#f5-medscimonit-25-2452){ref-type="fig"}). Moreover, a linear regression analysis showed a negative relationship between miR-409-3p and FNDC3B in HCC tissues with the rs2431\[A\] allele, but showed no relationship in HCC tissues with the rs2431\[G\] allele with a similar expression level of miR-409-3p ([Figure 5D](#f5-medscimonit-25-2452){ref-type="fig"}). These results suggested that *FNDC3B* is a target gene of miR-409-3p in HCC cells harboring the rs2431\[A\] allele but not rs2431\[G\].

Furthermore, the median time to recurrence after surgery for individuals with the GG or AG genotype at rs2431 (37.5 months) was substantially shorter than that of individuals with the AA genotype (62.8 months); the HR for recurrence was 1.314 (95% CI=1.042--1.657; *P*=0.023). A significant association was also found between the rs2431 genotype and tumor vascular invasion (*P*=0.046; [Supplementary Figure 6](#s19-medscimonit-25-2452){ref-type="supplementary-material"}).

To evaluate the role of *FNDC3B* in HCC, we also investigated the expression level of FNDC3B in tissue microarrays that contained HCC tissues from 361 patients by IHC staining. The staining density for FNDC3B in HCC tissues was significantly higher than that in adjacent non-tumor tissues (*P*\<0.0001) ([Figure 6A](#f6-medscimonit-25-2452){ref-type="fig"}). IRS\>1.5 was observed in 95 of 361 HCC tissues but only in 28 of the corresponding adjacent non-tumor tissues. Consistent with the rs2431 genotypes, the FNDC3B level was significantly associated with the length of survival (*P*=0.015; [Figure 6B](#f6-medscimonit-25-2452){ref-type="fig"}) and tumor vascular invasion (*P*=0.036). Additionally, FNDC3B levels in tumor tissues were significantly associated with the sex, age, tumor size, and TNM stage, as shown in [Supplementary Table 3](#s3-medscimonit-25-2452){ref-type="supplementary-material"}.

Discussion
==========

Despite recent advancements in diagnostic techniques and multimodal treatments, HCC remains one of the most aggressive and lethal diseases \[[@b1-medscimonit-25-2452],[@b6-medscimonit-25-2452]\]. In this study, using a genome-wide interrogation and replication approach, we identified 5 SNPs as independent genetic factors that affect the survival of patients with HCC. Using a Cox proportional hazards regression model, we established a 5-SNP model to predict survival in HCC. We validated the model using another independent sample set. We further showed that the prediction efficiency can be enhanced by incorporating TNM stage data into a new Nomogram model.

Our results indicate that individual genetic background plays an important role in both susceptibility and the outcome of HCC; this may explain observed variation in the response to the same treatment among patients with HCC. The SNP prediction model may provide a tool for the improved prediction of HCC progression and for guiding HCC monitoring or intervention, even before surgery. Additionally, the prediction model may provide new insight into the determinants of prognosis for patients with HCC. Further studies of the SNPs may identify new biological pathways affecting postoperative survival in HCC.

Since the progression of HCC is complicated, it is unlikely that a single genetic variant will have a drastic effect on clinical outcomes in HCC. However, several synergistic SNPs may have a combined effect on progression \[[@b7-medscimonit-25-2452],[@b8-medscimonit-25-2452]\]. Therefore, using a Cox proportional hazards regression model, we established a model that combined 5 SNPs to predict the long-term survival of patients with HCC after surgery. Strikingly, the survival rate 60 months after surgery calculated using our 5-SNP panel could serve as a reliable and accurate prognostic biomarker.

We chose rs2431, which has a MAF of 0.620 and is located in the 3′UTR of *FNDC3B* for detailed investigations. *FNDC3B* is located at Chr.3q26 and is a member of the fibronectin gene family \[[@b28-medscimonit-25-2452]\]. The disruption of FNDC3B inhibits adipocyte differentiation and proliferation, and the loss of FNDC3B expression causes a notable reduction in stress fiber formation, delaying cell adhesion, spread, and migration \[[@b29-medscimonit-25-2452]\]. Interestingly, FNDC3B over-expression could result in the malignant transformation of mammary and kidney epithelial cells and hepatocytes \[[@b30-medscimonit-25-2452]--[@b32-medscimonit-25-2452]\]. Our functional experiments confirmed this at the biochemical level. Taken together, the rs2431 genotype may be an invaluable target for guiding anti-metastasis therapeutic strategies.

The sample sizes of the discovery set (n=367), replication set (n=758), and validation set (n=316) might not be sufficient with respect to statistical power. In the near future, the association between the 5 genetic variants and survival time for individuals with HCC should be confirmed using larger sample sizes. To identify as many significant features as possible, we defined the threshold as 10^−3.5^. Using this threshold, 17 of 23 SNPs chosen for replication had a *P*-value that does not meet the median threshold for SNPs in previous GWASs (usually 10^−5^) \[[@b33-medscimonit-25-2452],[@b34-medscimonit-25-2452]\]. Multicenter studies should be conducted to further optimize the current model.

Conclusions
===========

In conclusion, using a genome-wide analysis, we developed survival prediction models for postoperative survival in patients with HCC. Hopefully, the performance and practicability of these models may facilitate clinical management, outcome prediction, and decision-making by physicians.

Supplementary Files
===================

###### 

Comparison of the allele frequencies of each SNP among discovery, replication and validation samples.

  SNP          Genotype   Discovery set (N=367)   Replication set (N=758)   Validation set (N=316)
  ------------ ---------- ----------------------- ------------------------- ------------------------
  rs10893585   CC         29.1%                   34.2%                     30.1%
  CT           48.4%      47.3%                   52.3%                     
  TT           22.5%      18.5%                   17.6%                     
  HWE          0.583      0.401                   0.277                     
  rs2431       AA         12.8%                   17.7%                     12.7%
  AG           45.5%      43.1%                   44.8%                     
  GG           41.7%      39.2%                   42.5%                     
  HWE          0.892      0.009                   0.757                     
  rs34675408   GT         7.7%                    6.4%                      7.8%
  TT           92.3%      93.6%                   92.2%                     
  HWE          0.446      0.365                   0.475                     
  rs6078460    AA         57.4%                   52.9%                     56.2%
  AG           37.0%      38.6%                   38.2%                     
  GG           5.6%       8.4%                    5.6%                      
  HWE          0.808      0.310                   0.617                     
  rs6766361    AA         6.3%                    7.9%                      5.2%
  CA           39.5%      39.1%                   39.5%                     
  CC           54.2%      52.9%                   55.2%                     
  HWE          0.639      0.624                   0.341                     

SNP -- single nucleotide polymorphisms; HWE -- Hardy-Weinberg equilibrium.

###### 

Univariate analyses of factors associated with overall survival of HCC in samples combined discovery and replication sets (n=1125).

  Variable                                      *P*-value                HR      95% CI   
  --------------------------------------------- ------------------------ ------- -------- -------
  Gender (Male *vs*. Female)                    0.483                    1.088   0.860    1.376
  Age, years (\>55 *vs*. ≤55)                   0.579                    0.954   0.808    1.126
  AFP, ng/ml (\>20 *vs*. ≤20)                   **5.36×10**^−^**^8^**    1.636   1.370    1.954
  ALT, ng/ml (\>75 *vs*. ≤75)                   0.177                    1.164   0.934    1.451
  Tumor size, cm (\>5 *vs*. ≤5)                 **5.64×10**^−^**^23^**   2.333   1.972    2.760
  Tumor number (multiple *vs*. single)          **0.021**                1.290   1.040    1.600
  Vascular invasion (yes *vs*. no)              **8.96×10**^−^**^30^**   2.594   2.200    3.059
  PVTT (yes *vs*. no)                           **1.33×10**^−^**^40^**   4.322   3.486    5.359
  Extrahepatic metastasis (yes *vs*. no)        **3.33×10**^−^**^6^**    2.305   1.621    3.278
  TNM stage (III--IV *vs*. I--II)               **2.52×10**^−^**^34^**   2.973   2.496    3.541
  BCLC stage (B--C *vs*. 0--A)                  **2.42×10**^−^**^21^**   2.569   2.114    3.122
  Child-Pugh stage (B *vs*. A)                  **1.91×10**^−^**^6^**    2.299   1.632    3.240
  Tumor differentiation (III--IV *vs*. I--II)   **1.19×10**^−^**^6^**    1.532   1.290    1.820
  Liver cirrhosis (yes *vs*. no)                0.099                    0.843   0.688    1.033
  Tumor encapsulation (none *vs*. complete)     **1.70×10**^−^**^7^**    1.574   1.328    1.866
  HBsAg (negative *vs*. positive)               0.544                    1.073   0.855    1.347
  HBcAb (negative *vs*. positive)               0.540                    0.909   0.670    1.233
  Anti-HCV (negative *vs*. positive)            0.354                    1.423   0.675    3.000

HCC -- hepatocellular carcinoma; AFP -- alpha fetoprotein; ALT -- alanine aminotransferase; BCLC -- Barcelona Clinic Liver Cancer; CI -- confidence interval; HBsAg -- hepatitis B surface antigen; HBcAb -- hepatitis B core antibody; HCV -- hepatitis C virus; HR -- hazard ratio; PVTT -- portal vein tumor thrombus; TNM -- tumor node metastasis.

###### 

Patient characteristics and distributions of immunoreactive scoring (IRS) by immunohistochemical staining of FNDC3B in 361 HCC tumor tissues on tissue microarrays.

  Variable                  Number   IRS ≤1.5   IRS\>1.5   *P*-value[\*](#tfn6-medscimonit-25-2452){ref-type="table-fn"}
  ------------------------- -------- ---------- ---------- ---------------------------------------------------------------
  Total                                                    
   Deceased                 193      133        60         **0.027**
   Alive                    168      133        35         
  MST, months               76.2     87.1       48.0       
  Gender                                                   
   Male                     298      211        87         **0.007**
   Female                   63       55         8          
  Age, years                                               
   ≤55                      231      162        69         **0.041**
   \>55                     130      104        26         
  AFP, ng/ml                                               
   ≤20                      135      101        34         0.706
   \>20                     226      165        61         
  ALT, ng/ml                                               
   ≤75                      316      234        82         0.675
   \>75                     45       32         13         
  Tumor size, cm                                           
   ≤5                       276      214        62         **0.003**
   \>5                      85       52         33         
  Tumor number                                             
   Single                   339      249        90         0.693
   Multiple                 22       17         5          
  Vascular invasion                                        
   Yes                      117      78         39         0.036
   No                       244      188        56         
  Extrahepatic metastasis                                  
   Yes                      5        5          0          0.178
   No                       356      261        95         
  TNM stage                                                
   I--II                    296      227        69         **0.006**
   III--IV                  65       39         26         
  Tumor differentiation                                    
   I--II                    272      205        67         0.184
   III--IV                  88       60         28         
  Liver cirrhosis                                          
   Yes                      79       63         16         0.170
   No                       279      201        78         
  Tumor encapsulation                                      
   None                     186      136        50         0.801
   Complete                 175      130        45         
  HBsAg                                                    
   Positive                 331      244        87         0.801
   Negative                 29       22         7          
  HBcAb                                                    
   Positive                 340      249        91         0.244
   Negative                 20       17         3          
  Anti-HCV                                                 
   Positive                 2        1          1          0.444
   Negative                 356      263        93         

Owing to a lack of information for some samples, the number of participants in each category may not add up to the total number. HCC -- hepatocellular carcinoma; AFP -- alpha-fetoprotein; ALT -- alanine aminotransferase; CI -- confidence interval; HBsAg -- hepatitis B surface antigen; HBcAb -- hepatitis B core antibody; HCV -- hepatitis C virus; HR -- hazard ratio; TNM -- tumor node metastasis.

χ^2^ -- test between different IRS groups and clinical variables.

###### 

The information of 23 survival related SNPs selected from discovery set.

  SNP          *P*-value of multiple linear regression   *P*-value of Kaplan-Meier estimate   Alleles DBSNP   Function     Amino acids   Gene list        Chr.
  ------------ ----------------------------------------- ------------------------------------ --------------- ------------ ------------- ---------------- ------
  rs10481370   1.67×10^−6^                               1.42×10^−4^                          A/G             Intron       None          CSMD1            8
  rs6078460    1.72×10^−6^                               1.70×10^−3^                          A/G             Intergenic   None          None             20
  rs11600756   2.93×10^−6^                               1.10×10^−4^                          C/T             Intron       None          KIRREL3          11
  rs11639771   5.08×10^−6^                               4.91×10^−5^                          C/T             Intergenic   None          None             16
  rs7579933    6.60×10^−6^                               4.52×10^−3^                          A/G             Intron       None          AAK1             2
  rs10790836   9.10×10^−6^                               3.42×10^−3^                          C/T             Intron       None          KIRREL3          11
  rs16910200   1.20×10^−5^                               9.37×10^−4^                          C/T             Intergenic   None          None             9
  rs1893185    1.18×10^−5^                               1.58×10^−4^                          C/T             Intron       None          PKNOX2           11
  rs6766361    1.65×10^−5^                               2.42×10^−4^                          A/C             Intergenic   None          None             3
  rs913493     2.30×10^−5^                               4.54×10^−5^                          A/G             Intron       None          PCDH9            13
  rs12897      3.74×10^−5^                               6.89×10^−4^                          A/G             Utr-3        None          FNDC3B           3
  rs2239910    4.63×10^−5^                               7.46×10^−7^                          A/C             Utr-3        None          SARM1, SLC46A1   17
  rs584368     5.19×10^−5^                               4.63×10^−6^                          C/T             Intergenic   None          None             11
  rs12504893   6.14×10^−5^                               5.00×10^−4^                          A/C             Intron       None          FSTL5            4
  rs1034756    6.54×10^−5^                               4.27×10^−4^                          A/G             Intergenic   None          None             7
  rs4617227    8.49×10^−5^                               3.06×10^−4^                          A/G             Intergenic   None          None             9
  rs10893585   9.29×10^−5^                               1.39×10^−4^                          A/G             Intron       None          KIRREL3          11
  rs3096380    9.63×10^−5^                               1.89×10^−5^                          A/G             Missense     LEU, PHE      FTSJD1           16
  rs3748735    9.84×10^−5^                               9.16×10^−4^                          C/T             Missense     ALA, THR      PLXNA2           1
  rs2431       2.11×10^−4^                               5.42×10^−4^                          A/G             Utr-3        None          FNDC3B           3
  rs7581876    2.41×10^−4^                               4.62×10^−9^                          A/G             Utr-3        None          AAK1             2
  rs34675408   2.59×10^−4^                               1.92×10^−4^                          G/T             Missense     HIS, GLN      OSMR             5
  rs6499496    2.85×10^−4^                               1.91×10^−5^                          A/G             Utr-3        None          FTSJD1           16

SNP -- single nucleotide polymorphisms; UTR -- untranslated region.

###### 

Associations between 23 SNPs and time to recurrence in the discovery, replication and combined samples with HCC.

  SNP              *P*-value (multiple linear regression analysis)               
  ---------------- ------------------------------------------------- ----------- ------------------------
  rs10481370       6.82×10^−6^                                       0.941       0.021
  **rs6078460**    **0.012**                                         **0.139**   **2.28×10**^−^**^8^**
  **rs11600756**   **1.02×10**^−^**^4^**                             **0.029**   **5.92×10**^−^**^4^**
  rs11639771       7.33×10^−4^                                       0.278       0.133
  rs7579933        2.21×10^−3^                                       0.574       0.460
  **rs10790836**   **8.35×10**^−^**^4^**                             **0.031**   **1.53×10**^−^**^3^**
  rs16910200       2.59×10^−5^                                       0.703       0.340
  rs1893185        0.016                                             0.108       0.025
  **rs6766361**    **3.71×10**^−^**^3^**                             **0.120**   **0.011**
  rs913493         2.39×10^−5^                                       0.989       4.61×10^−14^
  rs12897          0.020                                             0.153       0.028
  rs2239910        1.50×10^−3^                                       0.182       7.91×10^−3^
  rs584368         1.10×10^−4^                                       0.392       8.13×10^−10^
  rs12504893       5.18×10^−5^                                       0.629       0.141
  rs1034756        9.74×10^−5^                                       0.875       0.585
  rs4617227        2.89×10^−5^                                       0.655       0.080
  **rs10893585**   **1.59×10**^−^**^4^**                             **0.036**   **1.58×10**^−^**^3^**
  rs3096380        2.34×10^−3^                                       0.104       8.10×10^−12^
  rs3748735        6.43×10^−3^                                       0.670       0.469
  **rs2431**       **0.023**                                         **0.059**   **3.34×10**^−^**^3^**
  rs7581876        9.93×10^−3^                                       0.904       6.64×10^−3^
  **rs34675408**   **4.96×10**^−^**^3^**                             **0.051**   **1.60×10**^−^**^22^**
  rs6499496        8.07×10^−3^                                       0.752       0.410

SNP -- single nucleotide polymorphisms; HCC -- hepatocellular carcinoma.

###### 

Multivariate Cox regression analyses of each SNP (rs10893585, rs2431, rs34675408, rs6078460, and rs6766361) for overall survival of HCC samples combined discovery and replication sets (n=1125).

  Variable                                      *P*-value               HR      95.0% CI for HR   
  --------------------------------------------- ----------------------- ------- ----------------- -------
  **For rs10893585**                                                                              
  AFP, ng/ml (\>20 *vs*. ≤20)                   0.019                   1.249   1.037             1.504
  Tumor size, cm (\>5 *vs*. ≤5)                 9.63×10^−10^            2.162   1.689             2.768
  Tumor number (multiple *vs*. single)          0.010                   1.340   1.073             1.675
  Vascular invasion (yes *vs*. no)              7.72×10^−10^            1.987   1.596             2.473
  Extrahepatic metastasis (yes *vs*. no)        5.35×10^−3^             1.699   1.170             2.467
  Tumor differentiation (III--IV *vs*. I--II)   0.011                   1.262   1.056             1.508
  Tumor encapsulation (none *vs*. complete)     1.25×10^−4^             1.412   1.184             1.683
  Genotype (CC *vs*. CT+TT)                     **0.019**               0.802   0.667             0.964
  **For rs2431**                                                                                  
  AFP, ng/ml (\>20 *vs*. ≤20)                   0.032                   1.227   1.018             1.478
  Tumor size, cm (\>5 *vs*. ≤5)                 3.35×10^−10^            2.226   1.734             2.858
  Tumor number (multiple *vs*. single)          7.16×10^−3^             1.360   1.087             1.702
  Vascular invasion (yes *vs*. no)              4.03×10^−9^             1.938   1.555             2.416
  Extrahepatic metastasis (yes *vs*. no)        9.46×10^−3^             1.639   1.129             2.381
  Tumor differentiation (III--IV *vs*. I--II)   9.54×10^−3^             1.267   1.059             1.516
  Tumor encapsulation (none *vs*. complete)     7.14×10^−5^             1.433   1.200             1.711
  Genotype (AA *vs*. AG+GG)                     **8.61×10**^−^**^3^**   0.713   0.554             0.918
  **For rs34675408**                                                                              
  AFP, ng/ml (\>20 *vs*. ≤20)                   0.046                   1.210   1.004             1.458
  Tumor size, cm (\>5 *vs*. ≤5)                 1.47×10^−9^             2.145   1.675             2.747
  Tumor number (multiple *vs*. single)          0.016                   1.315   1.053             1.644
  Vascular invasion (yes *vs*. no)              2.29×10^−10^            2.033   1.632             2.531
  Extrahepatic metastasis (yes *vs*. no)        4.29×10^−3^             1.722   1.186             2.499
  Tumor differentiation (III--IV *vs*. I--II)   4.45×10^−3^             1.294   1.084             1.547
  Tumor encapsulation (none *vs*. complete)     1.04×10^−4^             1.417   1.188             1.689
  Genotype (GT *vs*. TT)                        **2.37×10**^−^**^5^**   1.863   1.396             2.486
  **For rs6078460**                                                                               
  AFP, ng/ml (\>20 *vs*. ≤20)                   0.051                   1.205   0.999             1.452
  Tumor size, cm (\>5 *vs*. ≤5)                 7.91×10^−11^            2.289   1.783             2.938
  Tumor number (multiple *vs*. single)          3.15×10^−3^             1.402   1.120             1.754
  Vascular invasion (yes *vs*. no)              6.03×10^−10^            2.001   1.607             2.493
  Extrahepatic metastasis (yes *vs*. no)        4.20×10^−3^             1.726   1.188             2.507
  Tumor differentiation (III--IV *vs*. I--II)   0.015                   1.248   1.044             1.493
  Tumor encapsulation (none *vs*. complete)     2.85×10^−4^             1.393   1.165             1.666
  Genotype (AA *vs*. AG+GG)                     **8.95×10**^−^**^3^**   1.258   1.059             1.494
  **For rs6766361**                                                                               
  AFP, ng/ml (\>20 *vs*. ≤20)                   0.034                   1.224   1.016             1.474
  Tumor size, cm (\>5 *vs*. ≤5)                 4.17×10^−10^            2.219   1.728             2.849
  Tumor number (multiple *vs*. single)          4.19×10^−3^             1.387   1.109             1.736
  Vascular invasion (yes *vs*. no)              3.66×10^−9^             1.935   1.554             2.410
  Extrahepatic metastasis (yes *vs*. no)        9.68×10^−3^             1.635   1.127             2.373
  Tumor differentiation (III--IV *vs*. I--II)   9.25×10^−3^             1.268   1.060             1.517
  Tumor encapsulation (none *vs*. complete)     4.66×10^−5^             1.444   1.210             1.724
  Genotype (AA+CA *vs*. CC)                     **1.04×10**^−^**^3^**   0.751   0.633             0.891

SNP -- single nucleotide polymorphisms; HCC -- hepatocellular carcinoma; AFP -- alpha-fetoprotein; CI -- confidence interval; HR -- hazard ratio.

###### 

genetic variants upon survival in the equation of Cox proportional hazard regression model of combined set.

  SNP          Cox coefficient   *P*-value     HR      95.0% CI for HR   
  ------------ ----------------- ------------- ------- ----------------- -------
  rs10893585   −0.268            4.28×10^−3^   0.765   0.637             0.919
  rs2431       −0.454            0.019         0.635   0.493             0.818
  rs34675408   0.570             3.10×10^−4^   1.768   1.326             2.356
  rs6078460    0.226             0.010         1.254   1.060             1.484
  rs6766361    −0.288            2.50×10^−3^   0.750   0.633             0.888

SNP -- single nucleotide polymorphisms; CI -- confidence interval; HR -- hazard ratio.

###### 

Comparison of overall survival between lower prediction value and higher prediction value groups divided by the Cutoff value from the 5-SNP prediction model.

  Sample                    Prediction value   Median time   Std. error   95.0% CI for median time   *P*-value   HR             95.0% CI for HR           
  ------------------------- ------------------ ------------- ------------ -------------------------- ----------- -------------- ----------------- ------- -------
  Discovery set (n=353)     Lower              117.3         31.846       54.915                     179.751     1.10×10^−7^    2.363             1.720   3.246
  Higher                    33.7               6.325         21.270       46.063                                                                          
  Replication set (n=740)   Lower              65.6          7.385        51.126                     80.074      2.62×10^−5^    1.529             1.254   1.863
  Higher                    37.4               4.399         28.745       45.988                                                                          
  Combined set (n=1093)     Lower              100.1         12.228       76.134                     124.066     1.45×10^−10^   1.725             1.460   2.038
  Higher                    35.5               3.575         28.493       42.507                                                                          
  Validation set (n=306)    Lower              80.2          8.702        63.11                      97.223      0.002          1.481             1.078   2.033
  Higher                    48.0               9.695         29.032       67.035                                                                          
  Entire cohort (n=1399)    Lower              81.1          5.868        69.599                     92.601      3.96×10^−9^    1.577             1.355   1.836
  Higher                    42.2               3.522         35.297       49.103                                                                          

Owing to failure of genotyping in several of the 5 SNPs for some samples, the number of participants in each set may not equal to the total number. SNP -- single nucleotide polymorphisms; CI -- confidence interval; HR -- hazard ratio.

###### 

Multivariate Cox regression analyses of 5-SNP prediction model for overall survival of HCC patients in each set.

  Variable                                          P-value                 HR      95.0% CI for HR           
  ------------------------------------------------- ----------------------- ------- ----------------- ------- --
  **For discovery set**                                                                                       
  AFP, ng/ml (\>20 *vs*. ≤20)                       0.547                   1.117   0.779             1.604   
  Tumor size, cm (\>5 *vs*. ≤5)                     8.05×10^−5^             2.613   1.621             4.212   
  Tumor number (multiple *vs*. single)              0.098                   1.403   0.940             2.093   
  Vascular invasion (yes *vs*. no)                  2.10×10^−3^             1.909   1.264             2.881   
  Extrahepatic metastasis (yes *vs*. no)            0.615                   1.185   0.611             2.299   
  Tumor differentiation (III--IV *vs*. I--II)       0.047                   1.409   1.004             1.976   
  Tumor encapsulation (none *vs*. complete)         1.60×10^−3^             1.748   1.236             2.473   
  Prediction value (higher *vs*. lower)             **9.13×10**^−^**^8^**   2.452   1.764             3.407   
  **For replication set**                                                                                     
  AFP, ng/ml (\>20 *vs*. ≤20)                       0.407                   1.097   0.881             1.367   
  Tumor size, cm (\>5 *vs*. ≤5)                     1.50×10^−7^             2.319   1.694             3.174   
  Tumor number (multiple *vs*. single)              0.249                   1.193   0.883             1.611   
  Vascular invasion (yes *vs*. no)                  6.04×10^−5^             1.760   1.335             2.319   
  Extrahepatic metastasis (yes *vs*. no)            0.032                   1.691   1.045             2.735   
  Tumor differentiation (III--IV *vs*. I--II)       0.039                   1.265   1.012             1.582   
  Tumor encapsulation (none *vs*. complete)         0.317                   1.117   0.899             1.389   
  Prediction value (higher *vs*. lower)             **0.018**               1.294   1.045             1.601   
  **For combined discovery and replication sets**                                                             
  AFP, ng/ml (\>20 *vs. vs*.20)                     0.058                   1.196   0.994             1.440   
  Tumor size, cm (\>5 *vs. vs*.5)                   3.20×10^−9^             1.879   1.525             2.315   
  Tumor number (multiple *vs*. single)              2.54×10^−3^             1.426   1.133             1.797   
  Vascular invasion (yes *vs*. no)                  6.52×10^−5^             1.611   1.275             2.036   
  Extrahepatic metastasis (yes *vs*. no)            0.013                   1.621   1.107             2.375   
  Tumor differentiation (III--IV *vs*. I--II)       0.036                   1.162   1.010             1.336   
  Tumor encapsulation (none *vs*. complete)         0.015                   1.253   1.044             1.503   
  Prediction value (higher *vs*. lower)             **1.80×10**^−^**^7^**   1.597   1.339             1.903   
  **For validation set**                                                                                      
  AFP, ng/ml (\>20 *vs*. ≤20)                       5.56×10^−3^             1.672   1.163             2.406   
  Tumor size, cm (\>5 *vs*. ≤5)                     1.80×10^−3^             2.236   1.349             3.707   
  Tumor number (multiple *vs*. single)              0.518                   1.151   0.751             1.763   
  Vascular invasion (yes *vs*. no)                  3.24×10^−7^             2.892   1.924             4.346   
  Extrahepatic metastasis (yes *vs*. no)            1.75×10^−4^             3.148   1.729             5.730   
  Tumor differentiation (III--IV *vs*. I--II)       0.173                   1.288   0.895             1.855   
  Tumor encapsulation (none *vs*. complete)         0.315                   1.183   0.852             1.643   
  Prediction value (higher *vs*. lower)             **4.65×10**^−^**^3^**   1.603   1.156             2.223   
  **For entire cohort**                                                                                       
  AFP, ng/ml (\>20 *vs*. ≤20)                       2.53×10^−3^             1.288   1.093             1.518   
  Tumor size, cm (\>5 *vs*. ≤5)                     1.23×10^−12^            1.977   1.638             2.386   
  Tumor number (multiple *vs*. single)              1.44×10^−3^             1.390   1.135             1.702   
  Vascular invasion (yes *vs*. no)                  1.83×10^−10^            1.910   1.565             2.330   
  Extrahepatic metastasis (yes *vs*. no)            5.77×10^−5^             1.923   1.398             2.644   
  Tumor differentiation (III--IV *vs*. I--II)       8.23×10^−3^             1.184   1.045             1.342   
  Tumor encapsulation (none *vs*. complete)         7.83×10^−3^             1.240   1.058             1.452   
  Prediction value (higher *vs*. lower)             **7.57×10**^−^**^9^**   1.573   1.349             1.834   

SNP -- single nucleotide polymorphisms; HCC --hepatocellular carcinoma; AFP -- alpha-fetoprotein; CI -- confidence interval; HR -- hazard ratio.

###### 

Comparison of recurrence-free survival between lower prediction value and higher prediction value groups divided by the Cutoff value from the 5-SNP prediction model.

  Sample                    Prediction value   Median time   Std. error   95.0% CI for median time   *P*-value   HR            95.0% CI for HR           
  ------------------------- ------------------ ------------- ------------ -------------------------- ----------- ------------- ----------------- ------- -------
  Discovery set (n=353)     Lower              38.6          9.849        19.262                     57.872      0.001         1.561             1.197   2.036
  Higher                    16.4               3.286         9.926        22.808                                                                         
  Replication set (n=740)   Lower              34.5          4.122        26.453                     42.613      5.54×10^−4^   1.369             1.146   1.637
  Higher                    16.9               2.346         12.336       21.531                                                                         
  Combined set (n=1093)     Lower              37.0          3.981        29.198                     44.802      3.38×10^−6^   1.419             1.224   1.645
  Higher                    16.6               1.711         13.246       19.954                                                                         
  Validation set (n=306)    Lower              39.0          5.365        28.485                     49.515      0.032         1.382             1.029   1.856
  Higher                    19.1               4.027         11.208       26.992                                                                         
  Entire cohort (n=1399)    Lower              37.3          3.570        30.270                     44.264      3.63×10^−7^   1.409             1.235   1.608
  Higher                    17.0               1.599         13.865       20.135                                                                         

Owing to failure of genotyping in several of the 5 SNPs for some samples, the number of participants in each set may not equal to the total number. SNP -- single nucleotide polymorphisms; CI -- confidence interval; HR -- hazard ratio.

###### 

Genetic variants and the TNM stages upon survival in the nomogram model of combined set.

  SNP               Nomogram coefficient   *P*-value     HR      95.0% CI for HR   
  ----------------- ---------------------- ------------- ------- ----------------- -------
  rs10893585        −0.255                 6.21×10^−3^   0.775   0.645             0.930
  rs2431            −0.450                 4.86×10^−4^   0.638   0.495             0.821
  rs34675408        0.506                  5.66×10^−4^   1.658   1.244             2.211
  rs6078460         0.228                  8.16×10^−3^   1.256   1.061             1.487
  rs6766361         −0.296                 6.25×10^−4^   0.744   0.628             0.881
  TNM stage (II)    0.412                  7.40×10^−4^   1.510   1.229             1.856
  TNM stage (III)   0.877                  6.73×10^−9^   2.404   1.939             2.980
  TNM stage (IV)    0.926                  8.15×10^−7^   2.524   1.723             3.698

SNP -- single nucleotide polymorphisms; CI -- confidence interval; HR -- hazard ratio; TNM -- tumor node metastasis.

###### 

Comparison of overall survival between lower prediction value and higher prediction value groups divided by the Cutoff value from the nomogram prediction model.

  Sample                    Prediction value   Median time   Std. error   95.0% CI for median time   *P*-value   HR             95.0% CI for HR           
  ------------------------- ------------------ ------------- ------------ -------------------------- ----------- -------------- ----------------- ------- -------
  Discovery set (n=353)     Lower              NA            NA           NA                         NA          1.39×10^−10^   3.311             2.297   4.773
  Higher                    32.8               4.322         24.296       41.238                                                                          
  Replication set (n=740)   Lower              100.1         NA           NA                         NA          3.25×10^−15^   2.300             1.870   2.829
  Higher                    30.2               3.909         22.572       37.895                                                                          
  Combined set (n=1093)     Lower              100.1         NA           NA                         NA          6.52×10^−24^   2.512             2.100   3.005
  Higher                    30.8               2.801         25.277       36.257                                                                          
  Validation set (n=306)    Lower              82.2          NA           NA                         NA          2.33×10^−10^   2.415             1.823   3.201
  Higher                    22.5               5.31          12.093       32.907                                                                          
  Entire cohort (n=1399)    Lower              100.1         NA           NA                         NA          5.04×10^−22^   2.503             2.176   2.886
  Higher                    28.1               2.856         22.535       33.731                                                                          

Owing to failure of genotyping in several of the 5 SNPs for some samples, the number of participants in each set may not equal to the total number. CI -- confidence interval; HR -- hazard ratio; NA -- not achieved.

###### 

Comparison of recurrence-free survival between lower prediction value and higher prediction value groups divided by the Cutoff value from the nomogram prediction model.

  Sample                    Prediction value   Median time   Std. error   95.0% CI for median time   *P*-value   HR             95.0% CI for HR           
  ------------------------- ------------------ ------------- ------------ -------------------------- ----------- -------------- ----------------- ------- -------
  Discovery set (n=353)     Lower              61.4          7.906        45.904                     76.896      1.35×10^−6^    1.997             1.508   2.643
  Higher                    14.0               2.239         9.644        18.422                                                                          
  Replication set (n=740)   Lower              55.6          5.099        45.607                     65.593      3.73×10^−15^   2.079             1.732   2.494
  Higher                    12.5               1.087         10.403       14.664                                                                          
  Combined set (n=1093)     Lower              56.0          4.332        47.543                     64.524      4.10×10^−20^   2.044             1.755   2.381
  Higher                    13.0               1.192         10.664       15.336                                                                          
  Validation set (n=306)    Lower              56.2          7.680        41.180                     71.286      2.57×10^−4^    1.751             1.297   2.365
  Higher                    16.8               1.877         13.087       20.446                                                                          
  Entire cohort (n=1399)    Lower              56.0          3.944        48.303                     63.764      5.42×10^−23^   1.984             1.732   2.273
  Higher                    14.0               1.065         11.913       16.087                                                                          

Owing to failure of genotyping in several of the 5 SNPs for some samples, the number of participants in each set may not equal to the total number. CI -- confidence interval; HR -- hazard ratio.

###### 

Principal component analysis (PCA) and quantile-quantile plot. (**A**) Plot of the first 2 components derived from a principal component analysis implemented in the software package GCTA, PCA showed little evidence of population stratification in our study populations. (**B**) Quantile-quantile plot of observed *P*-values. The purple crosses represent the distribution of *P*-values for the association of 630 573 autosomal SNPs in 367 patients with HCC. The observed versus expected χ^2^ test statistics showed no evidence for inflation of χ^2^ tests. SNP, single nucleotide polymorphisms.

###### 

Kaplan-Meier curves of survival times in HCC patients according to different genotypes at rs10893585, rs2431, rs34675408, rs6078460 and rs6766361. (**A**) Discovery set, (**B**) replication set, (**C**) combined set. Because of genotyping failure for some samples, the number of participants in each category may not add up to the total number. HCC -- hepatocellular carcinoma.

###### 

ROC analyses of the SNP survival prediction system in the time point of 60 months (5-year) after surgery of HCC patients. ROC -- receiver operating characteristics; SNP -- single nucleotide polymorphisms; HCC -- hepatocellular carcinoma.

###### 

ROC analyses of the Nomogram survival prediction model and TNM staging in the time point of 60 months (5-year) after surgery of HCC patients. ROC -- receiver operating characteristics; SNP -- single nucleotide polymorphisms; TNM -- tumor node metastasis.

###### 

Kaplan-Meier estimates of overall survival time in the discovery set (**A**), replication set (**B**) and entire cohort (**C**) based on the cut-off prediction value from the Nomogram prediction model.

###### 

Pearson chi-square estimate of tumor vascular invasion for rs2431 genotypes. Columnar section shows vascular invasion ratio in individuals with A or G genotypes.
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![Flow chart illustrating the study design.](medscimonit-25-2452-g001){#f1-medscimonit-25-2452}

![Manhattan plot of genome-wide *P*-values for associations between SNPs and survival time in patients with HCC. The effects of SNP genotypes on quantitative variables were investigated using multiple linear regression. The −log~10~*P*-values (*y*-axis) for SNPs are presented according to chromosomal positions (*x*-axis). SNP -- single nucleotide polymorphisms; HCC -- hepatocellular carcinoma.](medscimonit-25-2452-g002){#f2-medscimonit-25-2452}

![Kaplan-Meier estimates of survival time in the discovery set (**A**), replication set (**B**), combined discovery and replication sets (**C**), validation set (**D**), and the entire cohort (**E**) based on the cutoff prediction value from the 5-SNP prediction model. SNP, single nucleotide polymorphisms.](medscimonit-25-2452-g003){#f3-medscimonit-25-2452}

![Prognostic value of the Nomogram survival prediction model. (**A**) Genetic variants and TNM stages upon survival in the Nomogram model for the combined set. (**B**) Comparison of Harrell's c-indexes among the Nomogram model, the SNP model, and TNM stage in the combined discovery and replication sets (**left**) and validation set (**right**). The Harrell's c-indexes of the Nomogram model were statistically higher than those of other models for each sample set. (**C**) The calibration curve for predicting patient survival at 5 years in the combined discovery and replication sets (**left**) and validation set (**right**). Nomogram-predicted probability of overall survival is plotted on the x-axis; actual overall survival is plotted on the y-axis. (**D**) Kaplan-Meier estimates for survival time in the combined discovery and replication sets (upper) and validation set (lower), based on the cut-off prediction value from the Nomogram prediction model. TNM -- tumor node metastasis; SNP -- single nucleotide polymorphisms.](medscimonit-25-2452-g004){#f4-medscimonit-25-2452}

![Functional characterization of the rs2431 SNP. (**A**) Dual-luciferase reporter assays with the FNDC3B 3′UTR containing rs2431\[G\] or rs2431\[A\] in Hep3B (upper) and HEK293T (lower) cells. The regulatory activity of miR-409-3p on the 3′ UTR containing rs2431\[G\] was significantly weaker. (**B**) The suppression of FNDC3B expression in HCC cell lines containing the rs2431\[A\] allele was substantially stronger than that in HCC cell lines containing the rs2431\[G\] allele after miR-409-3p overexpression. (**C**) Representative images of IHC staining. Much stronger positive staining for FNDC3B was detected in HCC tissues with the rs2431\[G\] allele than with the rs2431\[A\] allele, and the signal was mainly detected in the cytoplasm. (**D**) A linear regression analysis showed a negative relationship between miR-409-3p and FNDC3B in HCC tissues with the rs2431\[A\] allele, but not in those with the rs2431\[G\] allele. Scale bar represents 200 μm. SNP -- single nucleotide polymorphisms; IHC -- immunohistochemistry; HCC -- hepatocellular carcinoma.](medscimonit-25-2452-g005){#f5-medscimonit-25-2452}

![Functional characterization of FNDC3B. (**A**) Representative images of IHC staining. Much stronger positive staining for FNDC3B was detected in HCC tissues than in adjacent non-tumor liver tissues. (**B**) Kaplan--Meier estimate of the length of survival for individuals with HCC, stratified by FNDC3B expression. Patients with lower FNDC3B expression in tumor tissues exhibited longer survival times. Scale bar represents 200 μm. IHC -- immunohistochemistry; HCC -- hepatocellular carcinoma.](medscimonit-25-2452-g006){#f6-medscimonit-25-2452}

###### 

Characteristics of individuals with HCC in the discovery, replication, and validation samples.

  Characteristics           Discovery set (N=367)   Replication set (N=758)   Validation set (N=316)                 
  ------------------------- ----------------------- ------------------------- ------------------------ ------ ------ ------
  Total                                                                                                              
   Deceased                 167                     45.5                      350                      46.2   154    48.7
   Alive                    200                     54.5                      408                      53.8   162    51.3
   MST, months              62.2                    --                        58.4                     --     58.0   --
  Gender                                                                                                             
   Male                     315                     85.8                      648                      85.5   272    85.9
   Female                   52                      14.2                      110                      14.5   44     14.1
  Age, years                                                                                                         
   ≤55                      211                     57.5                      460                      60.7   188    59.5
   \>55                     156                     42.5                      298                      39.3   128    40.5
  AFP, ng/ml                                                                                                         
   ≤20                      147                     40.1                      281                      37.1   124    39.2
   \>20                     218                     59.4                      477                      62.9   192    60.8
  ALT, ng/ml                                                                                                         
   ≤75                      316                     86.1                      610                      80.5   272    85.9
   \>75                     50                      13.6                      120                      15.8   44     14.1
  Tumor size, cm                                                                                                     
   ≤5                       183                     49.9                      382                      50.4   153    48.4
   \>5                      184                     50.1                      376                      49.6   163    51.6
  Tumor number                                                                                                       
   Single                   305                     83.1                      651                      85.9   270    85.3
   Multiple                 62                      16.9                      107                      14.1   46     14.7
  Vascular invasion                                                                                                  
   Yes                      143                     39.0                      318                      42.0   122    38.6
   No                       224                     61.0                      440                      58.0   193    61.1
  PVTT                                                                                                               
   Yes                      38                      10.4                      84                       11.1   30     9.5
   No                       329                     89.6                      674                      88.9   286    90.5
  Extrahepatic metastasis                                                                                            
   Yes                      18                      4.9                       30                       4.0    18     5.6
   No                       349                     95.1                      728                      96.0   298    94.4
  TNM stage                                                                                                          
   I--II                    279                     76.0                      586                      77.3   236    77.1
   III--IV                  88                      24.0                      172                      22.7   70     22.9
  BCLC stage                                                                                                         
   0--A                     124                     33.8                      268                      35.4   101    33.0
   B--C                     243                     66.2                      490                      64.6   205    67.0
  Child-Pugh stage                                                                                                   
   A                        348                     94.8                      722                      95.3   298    94.3
   B                        19                      5.2                       36                       4.7    18     5.7
  Tumor differentiation                                                                                              
   I--II                    247                     67.3                      513                      67.7   207    65.4
   III--IV                  113                     30.8                      227                      29.9   90     28.4
  Liver cirrhosis                                                                                                    
   Yes                      97                      26.4                      167                      22.0   70     22.2
   No                       270                     73.6                      590                      77.8   238    75.2
  Tumor encapsulation                                                                                                
   None                     212                     57.8                      426                      56.2   178    56.2
   Complete                 142                     38.7                      330                      43.5   128    40.5
  HBsAg                                                                                                              
   Positive                 309                     84.2                      601                      79.3   277    87.6
   Negative                 54                      14.7                      119                      15.7   39     12.4
  HBcAb                                                                                                              
   Positive                 343                     93.5                      661                      87.2   292    92.8
   Negative                 20                      5.5                       59                       7.8    14     4.2
  Anti-HCV                                                                                                           
   Positive                 3                       0.8                       6                        0.8    4      1.3
   Negative                 355                     96.7                      713                      94.1   303    96.8

Owing to a lack of information for some samples, the number of subjects in each category may not add up to the total number. AFP -- alpha-fetoprotein; ALT -- alanine aminotransferase; BCLC -- Barcelona Clinic Liver Cancer; CI -- confidence interval; HBsAg -- hepatitis B surface antigen; HBcAb -- hepatitis B core antibody; HCV -- hepatitis C virus; HR: hazard ratio; PVTT -- portal vein tumor thrombus; TNM -- tumor node metastasis.

###### 

Associations between 23 SNPs and length of survival in the discovery, replication, and combined samples with HCC.

  SNP              *P*-value (multiple linear regression analysis)               
  ---------------- ------------------------------------------------- ----------- ------------------------
  rs10481370       1.67×10^−6^                                       0.873       0.026
  **rs6078460**    **1.72×10**^−^**^6^**                             **0.038**   **2.24×10**^−^**^11^**
  **rs11600756**   **2.93×10**^−^**^6^**                             **0.007**   **4.39×10**^−^**^5^**
  rs11639771       5.08×10^−6^                                       0.985       0.570
  rs7579933        6.60×10^−6^                                       0.498       0.351
  **rs10790836**   **9.10×10**^−^**^6^**                             **0.042**   **4.79×10**^−^**^4^**
  rs16910200       1.20×10^−5^                                       0.455       0.490
  rs1893185        1.18×10^−5^                                       0.295       0.031
  **rs6766361**    **1.65×10**^−^**^5^**                             **0.042**   **3.90×10**^−^**^3^**
  rs913493         2.30×10^−5^                                       0.946       4.70×10^−20^
  rs12897          3.74×10^−5^                                       0.334       0.023
  rs2239910        4.63×10^−5^                                       0.178       5.38×10^−3^
  rs584368         5.19×10^−5^                                       0.246       1.81×10^−14^
  rs12504893       6.14×10^−5^                                       0.465       0.151
  rs1034756        6.54×10^−5^                                       0.498       0.284
  rs4617227        8.49×10^−5^                                       0.473       0.063
  **rs10893585**   **9.29×10**^−^**^5^**                             **0.018**   **5.67×10**^−^**^4^**
  rs3096380        9.63×10^−5^                                       0.122       1.34×10^−17^
  rs3748735        9.84×10^−5^                                       0.880       0.666
  **rs2431**       **2.11×10**^−^**^4^**                             **0.029**   **3.46×10**^−^**^3^**
  rs7581876        2.41×10^−4^                                       0.720       7.10×10^−4^
  **rs34675408**   **2.59×10**^−^**^4^**                             **0.032**   **1.33×10**^−^**^32^**
  rs6499496        2.85×10^−4^                                       0.718       0.146

###### 

Comparison of overall survival between lower prediction value and higher prediction value groups divided by the cut-off value from the 5-SNP or Nomogram prediction model in each subgroup of the entire cohort.

  Subgroup                 Prediction value   5-SNP prediction model   Nomogram prediction model                                                        
  ------------------------ ------------------ ------------------------ --------------------------- --------- -------------- -------- -------- --------- --------------
  Female (n=200)           Lower              100.1                    50.735                      149.465   0.061          100.1    82.703   117.497   1.21×10^−7^
  Higher                   52.0               23.841                   80.159                      33.3      17.540         49.127                      
  Male (n=1196)            Lower              100.4                    79.641                      121.092   1.51×10^−16^   NA       NA       NA        2.38×10^−22^
  Higher                   33.7               26.919                   40.548                      32.5      26.121         38.945                      
  Age ≤55 (n=832)          Lower              117.3                    57.128                      177.539   2.01×10^−7^    NA       NA       NA        6.26×10^−22^
  Higher                   35.1               24.792                   45.341                      27.2      21.908         32.425                      
  Age \>55 (n=564)         Lower              78.9                     62.626                      95.107    8.96×10^−6^    81.1     66.444   95.756    4.26×10^−8^
  Higher                   44.5               34.714                   54.286                      42.9      35.863         50.004                      
  AFP ≤20 (n=535)          Lower              NA                       NA                          NA        3.20×10^−4^    NA       NA       NA        4.01×10^−8^
  Higher                   56.0               NA                       NA                          58.0      48.056         67.944                      
  AFP \>20 (n=859)         Lower              64.5                     50.263                      78.803    3.82×10^−8^    100.1    67.752   132.448   9.93×10^−19^
  Higher                   29.2               23.884                   34.45                       23.5      18.450         28.617                      
  ALT ≤75 (n=1161)         Lower              100.1                    80.601                      119.599   5.39×10^−12^   100.1    NA       NA        1.22×10^−26^
  Higher                   36.3               28.233                   44.3                        30.8      25.299         36.234                      
  ALT \>75 (n=207)         Lower              81.1                     40.164                      122.036   0.025          81.1     43.595   118.605   0.004
  Higher                   31.8               19.317                   44.35                       29.4      10.532         48.268                      
  Cirrhosis (n=324)        Lower              100.1                    67.891                      132.309   5.26×10^−12^   100.1    NA       NA        3.24×10^−26^
  Higher                   32.4               24.954                   39.912                      28.0      22.763         33.237                      
  Non-cirrhosis (n=1064)   Lower              81.1                     NA                          NA        0.028          81.1     NA       NA        0.007
  Higher                   52.0               43.303                   60.697                      58.0      45.729         70.271                      
  BCLC 0--A (n=478)        Lower              100.1                    NA                          NA        3.60×10^−4^    100.1    NA       NA        0.005
  Higher                   64.5               NA                       NA                          28.7      25.319         32.014                      
  BCLC B--C (n=909)        Lower              53.8                     43.991                      63.542    5.26×10^−9^    61.9     41.736   81.998    5.35×10^−4^
  Higher                   23.7               17.58                    29.82                       32.8      26.565         38.968                      

Owing to failure of genotyping in several of the 5 SNPs for some samples, the number of subjects in each set may not equal to the total number. AFP -- alpha-fetoprotein; ALT -- alanine aminotransferase; BCLC -- Barcelona Clinic Liver Cancer; CI -- confidence interval; HBsAg -- hepatitis B surface antigen; HBcAb -- hepatitis B core antibody; HCV -- hepatitis C virus; HR -- hazard ratio; PVTT -- portal vein tumor thrombus; TNM -- tumor node metastasis; NA -- not achieved.
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